HowardKaufmanMD

Oncology • Boston, MA

Melanoma

Physician

Join to view full profile

Dr. Kaufman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kaufman's full profile

Already have an account?

Office
55 Fruit Street
Yawkey 7E
Boston, MA 02114
Phone+1 617-726-6607

Summary

I am a physician with an interest in melanoma and other types of skin cancer and using immunotherapy to treat cancer. I believe in developing an individualized approach for each patient to achieve the best possible outcome. I also support new clinical trials that bring cutting edge advances to patients that need new options.

Education & Training

Boston University Medical CenterResidency, Surgery, 1990 - 1995
National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1988 - 1990
Loyola University Chicago Stritch School of MedicineClass of 1986

Certifications & Licensure

MA State Medical License 1990 - 2025
ME State Medical License 2020 - 2021
NJ State Medical License 2014 - 2017
IL State Medical License 1986 - 2014
NY State Medical License 1997 - 2011
MD State Medical License 1989 - 1998
American Board of Surgery Surgery

Clinical Trials

XTX202 in Patients With Advanced Solid Tumors Start of enrollment: 2022 Jan 18
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
XTX101 Monotherapy and XTX101 and Atezolizumab Combination Therapy in Patients With Advanced Solid Tumors Start of enrollment: 2021 Sep 13
Recruiting
Phase 1, Phase 2
Roles: Contact

Publications & Presentations

PubMed

Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial.
Meghan J Mooradian, Florian J Fintelmann, Thomas J LaSalle, Judit Simon, Alexander Graur
Nature Communications. 2024-08-27
The prognostic value of the Merkel cell polyomavirus serum antibody test: A dual institutional observational study.
David M Miller, Sophia Z Shalhout, Kayla M Wright, Matt A Miller, Howard L Kaufman
Cancer. 2024-08-01
2 citations
Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?
Hongbin Wang, Mia Borlongan, Howard L Kaufman, Uyen Le, Hans J Nauwynck
Journal for Immunotherapy of Cancer. 2024-05-31

Books/Book Chapters

Cancer Immunotherapy: Principles and Practice
Lisa H. Butterfield, Howard L. Kaufman and Francesco H. MarincolaDemos Medical, New York City2017

Press Mentions

Triple-Negative Breast Cancer: Could a Cancer-Killing Virus Clear up Tumors?February 19th, 2023
Ankyra Therapeutics Appoints Leisha a. Emens, M.D., Ph.D., as Senior Vice President, Translational ResearchDecember 7th, 2022
Ankyra Therapeutics Announces $45 Million Series B Financing and Appoints Howard L. Kaufman M.D. As Chief Medical OfficerNovember 12th, 2021
Join now to see all